Hoth Therapeutics, Inc. (HOTH)
| Market Cap | 15.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.59M |
| Shares Out | 23.97M |
| EPS (ttm) | -0.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 680,683 |
| Open | 0.702 |
| Previous Close | 0.715 |
| Day's Range | 0.630 - 0.740 |
| 52-Week Range | 0.630 - 3.500 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 3.88 (+515.4%) |
| Earnings Date | n/a |
About HOTH
Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SA...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for HOTH stock is "Strong Buy" and the 12-month stock price forecast is 3.88.
News
These Emerging Biotechs Could Beat Alzheimer's Disease
The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions.
HOTH Stock Alert: Why Is Hoth Therapeutics Skyrocketing Today?
Investors in Hoth Therapeutics and HOTH stock have seen their investment go parabolic today on a key update for one of the company's drugs. The post HOTH Stock Alert: Why Is Hoth Therapeutics Skyrocketi...
Why Hoth Therapeutics Stock Is Soaring Today?
Hoth Therapeutics Inc (NASDAQ: HOTH) announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ. HT-ALZ is in development under t...
Best Biotech Penny Stocks to Buy Now? 3 to Watch in January
Check these three biotech penny stocks out for your watchlist right now The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Inform...
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using an Alzheimer's disease...
Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to th...
Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleas...
EXCLUSIVE: Hoth Therapeutics Gives Cannabinoid-Based Lupus Candidate Back To Zylö
Hoth Therapeutics Inc (NASDAQ: HOTH) has agreed to license its cannabinoid therapeutic, HT-005, for lupus patients back to Zylö Therapeutics. What Happened: In August 2019, Hoth Therapeutics and Zylö Th...
Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is plea...
Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with Nort...
Hoth Therapeutics: Emerging Biotech With a Diversified Pipeline
The biopharmaceutical industry is a high-risk, high-reward industry where stocks soar and plummet with the approval or rejection of drugs. In addition, a strict regulatory framework must govern this sec...
Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therape...
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical...
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc . (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflamm...
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Der...
NEW YORK, NY / PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence coho...
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Der...
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to comm...
Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial
NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety...
Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in hum...
Best Penny Stocks To Buy Now? 3 To Watch Amid SPRT Short Squeeze
Which penny stocks are investors watching amid the SPRT stock short squeeze? The post Best Penny Stocks To Buy Now?
Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Publishe...
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that i...
Hoth Therapeutics Starts Preclinical Study For Its Alzheimer's Candidate
Hoth Therapeutics Inc (NASDAQ: HOTH) has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model. The study aims to determine the effects of HT-ALZ on behavioral and pathological mark...
Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease
NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's H...
Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model
Hoth Therapeutics Inc (NASDAQ: HOTH) has announced that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces toll-like rece...
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment ...
NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in...
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the...
NEW YORK, June 28, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinica...
Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic...
NEW YORK, June 7, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with...